Las Vegas, NV -- (SBWIRE) -- 12/09/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Coronado Biosciences Inc (NASDAQ:CNDO), Kandi Technologies Group Inc (NASDAQ:KNDI), Elephant Talk Communications Corp (NYSEMKT:ETAK), Arca Biopharma Inc (NASDAQ:ABIO)
Coronado Biosciences Inc (NASDAQ:CNDO) managed to keep its gain at 3.61% on above-normal volume of 2.21M shares. The stock settled at $1.72 after floating in a range of $1.65 to $1.78. Its latest price has reached market capitalization of $58.38 million. Its 52-week range has been $1.25 to $12.70. Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company’s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic.
For How Long CNDO will fight for Profitability? Read This Trend Analysis report
Kandi Technologies Group Inc (NASDAQ:KNDI) traded up on a volume of 2.19 million, higher than its standard daily volume. Shares have gained 4.82% to $7.17. Over the last twelve months, the stock has gained 82.44% and faced a worst price of $3.37. Kandi Technologies Group, Inc. (Kandi), formerly Kandi Technologies, Corp., is engaged in designing, developing, manufacturing, and commercializing electrical vehicles (EVs), all-terrain vehicles (ATVs), go-karts, and specialized automobiles related products for the People’s Republic of China (PRC) and global markets. On April 25, 2012, the Company completed its acquisition of KO NGA Investment Limited and its subsidiaries, K S Asia Limited Group Limited, Yongkang K S Electric Limited and Yongkang Scrou Electric Co. (Yongkang Scrou).
For How Long KNDI’s Gloss will Attract Investors? Find out via this report
Elephant Talk Communications Corp (NYSEMKT:ETAK) settled 11.32% higher at $1.18 on above-normal volume of 2.18M shares during the last trading day. The stock has its 12-month high at $1.68 and 52-week low price was $0.53. It traded in a range of $1.01 to $1.18 during the last trading day. Elephant Talk Communications Corp. is a provider of mobile networking software and services. The Company provides operating software, managed services, cloud and Software as a Service (SaaS) solutions, an integrated transaction and delivery platform to the mobile telecommunications industry globally.
Why Should Investors Buy ETAK After the Recent Fall? Just Go Here and Find Out
In the last trading session, Arca Biopharma Inc (NASDAQ:ABIO) was down on high volume, trading at a volume of 2.56M versus its average daily volume of 1.56 million shares. At $1.55, the stock has attained market capitalization of 24.30 million. ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF).
Why Should Investors Buy ABIO After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)